FHIR IG analytics| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | ValueSet-2.16.840.1.113762.1.4.1178.43.json |
| FHIR Version | R4 |
| Source | https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1178.43/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43 |
| Version | 20220716 |
| Status | active |
| Date | 2022-07-16T01:02:12-04:00 |
| Name | SGLT2Ingredients |
| Title | SGLT2 Ingredients |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: The purpose of this value set is to represent concepts for medications of sodium glucose co-transporter 2 (SGLT2) ingredients.),(Data Element Scope: This value set may use a model element related to Allergy/Intolerance.),(Inclusion Criteria: Includes concepts that represent an allergy or intolerance for prescribable sodium glucose co-transporter 2 (SGLT2) ingredients only.),(Exclusion Criteria: No exclusions.) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
No narrative content found in resource
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113762.1.4.1178.43",
"meta": {
"versionId": "5",
"lastUpdated": "2023-12-21T17:43:03.000-05:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "AHA Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2025-03-10"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2022-07-16"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113762.1.4.1178.43"
}
],
"version": "20220716",
"name": "SGLT2Ingredients",
"title": "SGLT2 Ingredients",
"status": "active",
"experimental": false,
"date": "2022-07-16T01:02:12-04:00",
"publisher": "AHA Steward",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: The purpose of this value set is to represent concepts for medications of sodium glucose co-transporter 2 (SGLT2) ingredients.),(Data Element Scope: This value set may use a model element related to Allergy/Intolerance.),(Inclusion Criteria: Includes concepts that represent an allergy or intolerance for prescribable sodium glucose co-transporter 2 (SGLT2) ingredients only.),(Exclusion Criteria: No exclusions.)",
"compose": {
"include": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept": [
{
"code": "1373458",
"display": "canagliflozin"
},
{
"code": "1488564",
"display": "dapagliflozin"
},
{
"code": "1545653",
"display": "empagliflozin"
},
{
"code": "1992672",
"display": "ertugliflozin"
}
]
}
]
},
"expansion": {
"identifier": "urn:uuid:5c4f4503-ba0a-45f6-aaa2-c4ba28dfaaa3",
"timestamp": "2025-05-23T19:08:06-04:00",
"total": 4,
"contains": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1373458",
"display": "canagliflozin"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1488564",
"display": "dapagliflozin"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1545653",
"display": "empagliflozin"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1992672",
"display": "ertugliflozin"
}
]
}
}